Peter Blume-Jensen - Nov 14, 2022 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
President and CEO, Director
Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Stock symbol
ACRV
Transactions as of
Nov 14, 2022
Transactions value $
$0
Form type
4
Date filed
11/16/2022, 06:05 PM
Previous filing
Nov 9, 2022
Next filing
Jun 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Award $0 +935K +107.21% $0.00 1.81M Nov 14, 2022 Direct F1
transaction ACRV Common Stock Award $0 +503K +27.87% $0.00 2.31M Nov 14, 2022 Direct F2
transaction ACRV Common Stock Award $0 +60.1K +2.6% $0.00 2.37M Nov 14, 2022 Direct F3
transaction ACRV Common Stock Award $0 +26.7K +9.08% $0.00 321K Nov 14, 2022 See footnote F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRV Stock Option (Right to Buy) Award $0 +180K $0.00 180K Nov 14, 2022 Common Stock 180K $12.50 Direct F6
transaction ACRV Stock Option (Right to Buy) Award $0 +80.1K $0.00 80.1K Nov 14, 2022 Common Stock 80.1K $12.50 See footnote F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 1/3rd of the RSUs shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in eight equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. This RSU grant to the Reporting Person constitutes a number of shares equal to 3.5% of the total outstanding shares of the Issuer as of the pricing of the Issuer's initial public offering, on a fully diluted basis after giving effect to the offering.
F2 These shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 1/3rd of the RSUs shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in eight equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. This RSU grant to the Reporting Person constitutes a number of shares equal to 1.885% of the total outstanding shares of the Issuer as of the pricing of the Issuer's initial public offering, on a fully diluted basis after giving effect to the offering, meant to cover estimated tax liability at the time of settlement of the RSU award referred to in footnote 1.
F3 These shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, twenty-five percent (25%) of the RSUs shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
F4 These shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F5 These securities are held by Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F6 Twenty-five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the grant date, and the remaining shares subject to the option shall vest in 36 equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.